Skip to main content

Publications

Recent publications about Molecular Breast Imaging (MBI)
phvlwb
In MBI

Experts issue appropriate use criteria for molecular breast imaging

“Published August 26 in the Journal of Nuclear Medicine Technology, the criteria were developed by a workgroup of 10 experts convened by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and included representatives from the American College of Radiology (ACR), the American College of Nuclear Medicine (ACNM), the Society of Breast Imaging (SBI), the American Society of Breast Surgeons (ASBS), the American Society of Clinical Oncology (ASCO), and the European Association of Nuclear Medicine (EANM).”

View and download AuntMinnie story here.

View and download SNMMI Appropriate Use Criteria for Molecular Breast Imaging (MBI) summary.

phvlwb
In MBI

Molecular Breast Imaging-guided Percutaneous Biopsy of Breast Lesions: A New Frontier on Breast Intervention

Beatriz E Adrada, MD, Tanya Moseley, MD, S Cheenu Kappadath, PhD, Gary J Whitman, MD, Gaiane M Rauch, MD, PhD

Abstract: Molecular breast imaging (MBI) is an increasingly recognized nuclear medicine imaging modality to detect breast lesions suspicious for malignancy. Recent advances have allowed the development of tissue sampling of MBI-detected lesions using a single-headed camera (breast-specific gamma imaging system) or a dual-headed camera system (MBI system). In this article, we will review current indications of MBI, differences of the two single- and dual-headed camera systems, the appropriate selection of biopsy equipment, billing considerations, and radiation safety. It will also include practical considerations and guidance on how to integrate MBI and MBI-guided biopsy in the current breast imaging workflow.

Full Article in Journal of Breast Imaging, Volume 2, Issue 5, September/October 2020, Pages 484–491

phvlwb
In MBI

Supplemental screening in the dense breast: does molecular breast imaging have a role?

Deborah J. Rhodes, MD

With the passage of a 2019 US federal law directing FDA to ensure that mammography facilities provide a summary to patients categorizing their breast density and explaining how it can influence mammography accuracy, providers will increasingly be called on to discuss the options for supplemental screening. Numerous studies have elucidated the extent of masking that occurs with mammography screening in dense breasts when mammography is compared with other supplemental screening modalities. Despite this evidence, there is currently no consensus among experts or imaging societies as to whether or with what supplemental screening should be performed, leaving providers to counsel patients regarding the balance of benefits and harms.

Full Article in Menopause: January 2020 – Volume 27 – Issue 1 – p 110-112